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Systemic neonatal infection is a serious complication in preterm and term infants and is deﬁned as a complex
clinical syndrome caused by bacteria, fungi and virus. Sepsis remains among the leading causes of death
in both developed and underdeveloped countries above all in the neonatal period. Earlier diagnosis may
offer the ability to initiate treatment to prevent adverse outcomes. There have been many studies on various
diagnostic haematological markers like acute phase reactants, C-reactive protein, procalcitonin, interleukins
and presepsin. However, there is still no single test that satisﬁes the criteria as being the ideal marker for the
early diagnosis of neonatal sepsis. In this regard, metabolomic analysis seems to be a promising method for
determining metabolic variations correlated with systemic neonatal infections.
© 2014 Elsevier Ireland Ltd. All rights reserved.
Introduction
Sepsis is a clinical syndrome characterized by a series of im-
munological, metabolic, haemodynamic and respiratory alterations
secondary to an infective process caused by an abnormal systemic
inﬂammatory response syndrome (SIRS) in the organism. Systemic
neonatal infections are an important long-term cause of mortality
and morbidity for preterm and hospitalized newborn babies. In
the United States the annual incidence of serious sepsis has been
estimated at 0.3% and neonatal mortality is 10.3%, with most deaths
occurring within 48 hours from the onset of the infection [1].
Mortality rates vary depending on the organisms considered and
the data of the National Institute of Child Health and Human Devel-
opment Neonatal Research Network report mortality rates between
10 and 20% for gram positive infections, 36% for gram negative ones
and 32% for fungal infections [2]. In the ﬁeld of systemic neonatal
infections, besides those caused by bacteria and fungi, also to be
considered are those caused by viruses that can be transmitted from
mother to child (CMV, HSV1, HSV2) and those caused by viruses
capable of causing bronchiolitis and respiratory pathologies with
viremia (such as the respiratory syncytial virus) [3]. The perinatal
period is a time at risk for exposure to various virulent organisms
that may come from the uterus, the birth canal, hospitalization,
invasive procedures and family members and visitors. The high
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incidence and seriousness of neonatal systemic infections are to be
attributed to the reciprocal inﬂuence of different factors such as
immaturity of the immune defence mechanisms, especially weak
in preterms, and the complex interaction between the infecting
pathogen and the host. Sepsis is a clinical condition caused by in-
fectious microorganisms and induced by mediators of inﬂammation
that cause alteration of the immune, inﬂammatory and coagulative
equilibrium [4]. Neonatal sepsis concerns infections with onset
within the ﬁrst 28 days of life for a term neonate and within 4
weeks after the predicted birth date for preterms; in this period
early diagnosis is complicated by the presence of non-infective
conditions similar to those of sepsis, especially in low birth weight
preterms and by the lack of optimal diagnostic tests. Despite the
many and extensive investigations that have been performed in the
last decades, there is still no single test that satisﬁes the criteria as
being the ideal marker for the early diagnosis of neonatal sepsis.
Since neonatal sepsis is a complex disorder involving different
organs which leads to wide variations in the organism’s metabo-
lites, analysis of the entire metabolome is a promising method for
determining metabolic variations correlated with sepsis.
Systemic infections and metabolomics
Systemic infections are among the major causes of neonatal
mortality and long-term disability in very low birth weight (VLBW)
children. Although biomolecular knowledge on the pathophysiology
of sepsis has improved over the years, for this pathology no mark-
ers making early diagnosis possible have yet been identiﬁed nor
have prognostic biomarkers of high sensitivity and speciﬁcity been
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Table 1
Metabolomic studies that have analyzed the metabolic proﬁles of septic patients.
1H NMR, 1H-nuclear magnetic resonance; HCMV, human cytomegalovirus; SIRS, systemic inﬂammatory response syndrome; UPLC–Q-TOF-MS, ultra performance liquid
chromatography quadrupole time-of-ﬂight mass spectrometry; LC, liquid chromatography; GC/MS, gas chromatography/mass spectrometry.
found [5]. In recent years, several single biochemical parameters of
sepsis have been proposed such as C-reactive protein (CRP), white
cell count, ﬁbrinogen, D-dimer, platelet count, procalcitonin (PCT),
serum amyloid protein, interleukins and presepsin [6,7]. However,
certain recently developed investigative techniques provide a holis-
tic vision of the biological system in its entirety. Among these,
metabolomics (the most recent of the omic sciences) appears to
be the most promising. It is deﬁned as the study of the complex
system of metabolites and, besides taking into consideration one
or a few metabolites and their relative metabolic processes, it is
capable of examining the entire metabolic proﬁle of an individual.
Recent studies show the eﬃcacy of metabolomics in providing
signiﬁcant information useful in arriving at an early diagnosis of
several neonatal pathologies [8]. The need for a highly sensitive and
predictive test in the neonatal period for identifying and correctly
classifying the highest possible number of septic neonates make
metabolomics a method of great diagnostic potential. Works on
metabolomics concerning sepsis conducted on animals and humans
have recently been published (Table 1). It is interesting to see in
the different studies that among the metabolites that characterize
septic patients there are clear analogies. Firstly, both in studies on
rats [9,10] and human patients [11–13] increases in metabolites
in septic patients compared to controls (in plasma and urine)
which are part of the oxidative metabolism of fatty acids (such as
hydroxybutyrate, acylcarnitines and acetoacetate) have been found.
It is known that fatty acids, once released from adipose tissue and
transported into the cytoplasm of hepatic and muscle cells, are
activated in the form of esters of coenzyme A. The latter, by means
of a complex mechanism of transesteriﬁcation with carnitine, cross
the mitochondrial membrane where they enter the beta oxidation
cycle with the formation of acetyl-CoA. The latter is used by the
liver for the synthesis of the ketone bodies (3-hydroxibutyrate
and acetoacetate) while in muscle tissue it directly enters the
cycle of the tricarboxylic acids with freeing of CO2 and H2O and
formation of ATP. It has been observed that conditions of stress
of the organism that cause an increase in lipolysis and/or protein
catabolism to satisfy the need for a surplus of energy, as in the
case of sepsis, determine an increase in renal excretion of carnitine
and other metabolites involved in the oxidative metabolism of fatty
acids. In several works [9,12–14], lactate, together with glucose and
myoinositol content in the blood and urine of septic patients com-
pared to controls has also been found to be higher. These results
can be explained by taking into account that sepsis corresponds
to a systemic inﬂammation caused by the anomalous presence of
bacterial or viral antigens and involves different mechanisms, such
as hypoxia and oxidative stress. At the outset of the infection,
inhibition of glycogen synthesis is observed and this leads to a
major availability of global glucose and greater cell absorption [15].
Glucose absorption appears increased in organs containing a large
population of phagocytic cells (liver, spleen, intestine, lungs). Sepsis
is also capable of signiﬁcantly modifying cytoplasmatic glycolysis at
the transcriptional level. In particular, the key enzymes of glycolysis
and those of the mitochondrial respiratory chain are temporarily
under-expressed. It has been seen that in the muscle of septic rats
the activity of pyruvate dehydrogenase is reduced, at the same
time with an increase in the activity of pyruvate dehydrogenase
kinase (PDK), its inhibitor. The net result of all these changes
is the reduction of the pyruvate that enters the mitochondria
while the conversion of pyruvate into lactate is accelerated. This
is conﬁrmed by the fact that in patients with septic shock there
is an increased use of glucose and an increase in the production
of lactate at the anaerobic level [10,14]. Brieﬂy stated, alterations
in the glucose metabolism in critical conditions can be seen as
a redistribution of glucose consumption from the mitochondrial
oxidative phosphorylation to other metabolic pathways, such as
the production of lactate and the pentose phosphate pathway. All
this would explain the same metabolic pattern found in several
septic patients assessed by means of metabolomics. Still few are the
works published in the literature on metabolomics and systemic
infections in pediatric patients and in particular in neonates. In
a quite recent study by Mickiewicz et al. [13] it is demonstrated
that the metabolomic approach may be useful in the diagnosis
and prognosis of septic shock in pediatric intensive care units
(PICUs). The authors examined serum samples collected from 60
patients with septic shock (by Gram- and/or Gram+), 40 patients
with SIRS and 40 healthy children by nuclear magnetic resonance
spectroscopy spectra. Some of the metabolite concentrations iden-
tiﬁed in serum samples changed markedly, thus indicating their
inﬂuence on the separation between patient groups. These metabo-
lites represent a composite biopattern of the pediatric metabolic
response to septic shock and might be considered as the basis for a
biomarker panel for the diagnosis of septic shock and its mortality
in PICUs. In another work by Fanos et al. [12], urine samples of
neonates infected by human cytomegalovirus (HCMV) were ana-
lyzed by means of 1H-nuclear magnetic resonance spectroscopy
combined with multivariate statistical analysis. The authors suggest
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the use of metabolomics as a new and useful instrument also in
the study of congenital HCMV infections. In the literature we can
also ﬁnd preliminary data on metabolomics and viral bronchiolitis
in the neonate [16]. As concerns bacterial pneumonia infections,
it is interesting to see that thanks to the use of metabolomics it
has been possible to differentiate the urine metabolic proﬁle in
pneumonia caused by pneumococcus from the metabolic proﬁles of
viral pneumonia and other bacterial forms [17].
Conclusions
Present-day methods and procedures for the diagnosis of sys-
temic neonatal infections are hindered by low sensitivity and
long response times. They are inadequate to satisfy the need to
proceed to a rapid, timely and eﬃcacious therapeutic treatment.
Metabolomics is showing promise of becoming a most effective
method in neonatology, especially because it not only allows early
diagnosis of different pathologies and their monitoring, but is even
capable of predicting their onset and the capacity to respond to
therapy, thus making possible a tailored management of complex
pediatric disorders. Taking into account all the studies published
up to now, metabolomics appears to be a promising and useful
instrument also in the diagnosis of sepsis. However, it will be
necessary in the future to conﬁrm these results by means of further
studies so as to arrive at a more detailed picture from the metabolic
standpoint, especially in systemic neonatal infections.
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